MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Meridian Bioscience, Inc.
VIVO Details
Meridian Bioscience, Inc. (NASDAQ: VIVO) is a life sciences company that develops, manufactures, sells, and distributes diagnostic testing systems and kits, primarily for gastrointestinal and respiratory infectious diseases, elevated blood lead levels, and bulk antigens, antibodies, and bioresearch reagents used by other diagnostic manufacturers and researchers. Diagnostic and Life Sciences are the company's two operating segments.
Latest News:
FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
VIVO Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
VIVO's stock price has increased 6.45% in the past three months and is currently leaning towards the lower band of its 52-week range of USD 17.00 to USD 30.65. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 52.67. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 18.80.
Considering the uptick in the stock price, technical indicators, and current valuation, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 19.97, down 1.19%, as of January 06, 2022, 03:42 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.